Abstract:BackgroundCyclic peptide-based drug discovery is attracting increasing interest owing to its potential to avoid target protein depletion. In drug discovery, it is important to maintain the biostability of a drug within the proper range. Plasma protein binding (PPB) is the most important index of biostability, and developing a computational method to predict PPB of drug candidate compounds contributes to the acceleration of drug discovery research. PPB prediction of small molecule drug compounds using machine learning has been conducted thus far; however, no study has investigated cyclic peptides because experimental information of cyclic peptides is scarce.ResultsFirst, we adopted sparse modeling and small molecule information to construct a PPB prediction model for cyclic peptides. As cyclic peptide data are limited, applying multidimensional nonlinear models involves concerns regarding overfitting. However, models constructed by sparse modeling can avoid overfitting, offering high generalization performance and interpretability. More than 1000 PPB data of small molecules are available, and we used them to construct a prediction models with two enumeration methods: enumerating lasso solutions (ELS) and forward beam search (FBS). The accuracies of the prediction models constructed by ELS and FBS were equal to or better than those of conventional non-linear models (MAE = 0.167–0.174) on cross-validation of a small molecule compound dataset. Moreover, we showed that the prediction accuracies for cyclic peptides were close to those for small molecule compounds (MAE = 0.194–0.288). Such high accuracy could not be obtained by a simple method of learning from cyclic peptide data directly by lasso regression (MAE = 0.286–0.671) or ridge regression (MAE = 0.244–0.354).ConclusionIn this study, we proposed a machine learning techniques that uses low-dimensional sparse modeling to predict the PPB value of cyclic peptides computationally. The low-dimensional sparse model not only exhibits excellent generalization performance but also improves interpretation of the prediction model. This can provide common an noteworthy knowledge for future cyclic peptide drug discovery studies.

Kernel Risk Sensitive Loss-based Echo State Networks for Predicting Therapeutic Peptides with Sparse Learning.

Subspace Projection-Based Weighted Echo State Networks for Predicting Therapeutic Peptides

Therapeutic peptides identification via kernel risk sensitive loss-based k-nearest neighbor model and multi-Laplacian regularization

A Sparse Feature Extraction Method with Elastic Net for Drug-Target Interaction Identification.

Sequence homology score-based deep fuzzy network for identifying therapeutic peptides

PreTP-EL: Prediction of Therapeutic Peptides Based on Ensemble Learning

Design of Exoskeleton Brain-Like Intelligent Trajectory Prediction Model Based on Echo State Network

Structured Sparse Regularized TSK Fuzzy System for Predicting Therapeutic Peptides

Pep-CNN: an Improved Convolutional Neural Network for Predicting Therapeutic Peptides

ACP-DL: A Deep Learning Long Short-Term Memory Model to Predict Anticancer Peptides Using High-Efficiency Feature Representation

Computational prediction of plasma protein binding of cyclic peptides from small molecule experimental data using sparse modeling techniques

Semi-supervised Echo State Network with Partial Correlation Pruning for Time-Series Variables Prediction in Industrial Processes

Subspace Echo State Network for Multivariate Time Series Prediction

ACPNet: A Deep Learning Network to Identify Anticancer Peptides by Hybrid Sequence Information

pLMFPPred: a novel approach for accurate prediction of functional peptides integrating embedding from pre-trained protein language model and imbalanced learning

Efficient prediction of anticancer peptides through deep learning

DeepTPpred: A Deep Learning Approach with Matrix Factorization for Predicting Therapeutic Peptides by Integrating Length Information

Protein-chemical Interaction Prediction Via Kernelized Sparse Learning SVM.

PreTP-2L: identification of therapeutic peptides and their types using two-layer ensemble learning framework

ITP-Pred: an interpretable method for predicting, therapeutic peptides with fused features low-dimension representation

An in silico scheme for optimizing the enzymatic acquisition of natural biologically active peptides based on machine learning and virtual digestion